Slingshot Insights | Ibrx Overview

IBRX Overview

Upcoming Projects (IBRX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (IBRX)

Understanding ImmunityBio's Complete Response Data with their off-the-shelf CD19 CAR‑NK Cell Therapy in Waldenström Lymphoma
Ticker: IBRX
Executed On: Jan 26, 2026 at 04:30 PM EST
Discussing new data on AstraZeneca’s Imfinzi (durvalumab) in NMIBC and Roche’s Tecentriq (atezolizumab) in MIBC Presented at ESMO 2025
Tickers: AZN, RHHBY, NTRA, PFE, IBRX, CGON, MRK, JNJ, URGN, AURA, TARA, BMY
Executed On: Dec 08, 2025 at 06:00 PM EST
A Second View: Examining ImmuityBio's novel therapeutic approach to BCG-unresponsive high grade NMIBC combining Anktiva (N-803) with intravesical BCG and its recent Phase 2/3 QUILT3.032 Trial results presented at ASCO-GU
Ticker: IBRX
Executed On: Mar 22, 2022 at 01:30 PM EDT
Examining ImmuityBio's novel therapeutic approach to BCG-unresponsive high grade NMIBC combining Anktiva (N-803) with intravesical BCG and its recent Phase 2/3 QUILT3.032 Trial results presented at ASCO-GU
Ticker: IBRX
Executed On: Mar 02, 2022 at 09:30 AM EST
Examining the potential of ImmunityBio’s combination immunotherapy, Nant Cancer Vaccine in pancreatic cancer
Ticker: IBRX
Executed On: Feb 01, 2022 at 03:00 PM EST

Upcoming & Overdue Catalysts (IBRX)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (IBRX)

Don’t see a strategic initiative related to the company you care about? Create your own!